Several studies have demonstrated the clinical benefits of PARP inhibitors for these patients, and the US FDA has approved their use for breast [47,48], ovarian [49], and prostate cancer [50,51,52] patients with PALB2 or BRCA1 mutations. The gene discussed is BRCA1; the disease is prostate carcinoma.